HEMATOLOGY

Sagar Lonial, MD, discussed some of the emerging agents for the treatment of patients with late relapse in multiple myeloma.

Eytan M. Stein, MD, sheds light on the current treatment landscape of AML and underscored the importance of molecular monitoring. In addition, he highlights where the field of AML is headed.

The combination regimen of venetoclax and obinutuzumab is seeking FDA approval; a supplemental new drug application has been submitted to the FDA for the combination as a treatment for patients with previously untreated chronic lymphocytic leukemia who also have coexisting medical conditions, according to an announcement from Genentech (Roche).

Natalie S. Grover, MD, discusses the potential role of CD30-specific chimeric antigen receptor T cells in patients with relapsed/refractory Hodgkin Lymphoma.

Jacqueline C. Barrientos, MD, MS, discusses emerging agents and combinations in CLL based on recent trial data.

Sangmin Lee, MD, discusses a potential way to overcome resistance to venetoclax in acute myeloid leukemia.

Richard M. Stone, MD, discusses emerging agents and combinations for older patients with AML, along with his preferences for treatment.

A look back at all the FDA news in oncology from the month of February 2019, including several new approvals, priority review designations, and an orphan drug desgination.

In an interview with&nbsp;<em>Targeted Oncology&nbsp;</em>during the 2018 ASH Annual Meeting, Elizabeth Lihua Budde, MD, PhD, discussed the results seen from this trial for patients with FL and DLBCL. She shared plans for the next steps and how this treatment may impact the patient population.

In an interview with Targeted Oncology, Nathan H. Fowler, MD, discussed the current research for the treatment landscape of relapsed/refractory follicular lymphoma, including 3 clinical trials at MD Anderson that are currently accruing patients with this disease.

In an interview with&nbsp;<em>Targeted Oncology,&nbsp;</em>Stephen Douglas Smith, MD, discussed recent advancements in FL, new treatments currently being evaluated in clinical trials, and the challenges that still exist within this space.

Elizabeth Lihua Budde, MD, PhD, discusses how the phase I/Ib clinical trial for mosunetuzumab in patients with follicular lymphoma is different than other clinical trials.

Based on data from the phase III AUGMENT trial, a supplemental new drug application for the&nbsp;R²&nbsp;regimen of lenalidomide plus rituximab has been granted a priority review designation by the FDA&nbsp;as a therapy for patients with previously treated follicular lymphoma and marginal zone lymphoma.

In an interview with <em>Targeted Oncology&nbsp;</em>during the 2019 TCT meeting, Frederick L. Locke, MD, discusses the optimal management of CAR T-cell therapy-related adverse events.

Based on data from an ongoing preliminary trial, CD30-targeting chimeric antigen receptor T cells are safe and active in the treatment of patients with relapsed/refractory Hodgkin lymphoma.

According to findings from the phase III COLUMBA trial in patients with relapsed/refractory multiple myeloma, a&nbsp;subcutaneous formulation of daratumumab &nbsp;is noninferior in terms of inefficacy and pharmacokinetics to the standard&nbsp;intravenous daratumumab.

All but 1 of the first 19 patients with relapsed/refractory AML randomized to receive iodine-131 apamistamab had a complete response and went on to have successful engraftment of allogeneic hematopoietic stem cell transplant,&nbsp;according to preliminary results from the ongoing, randomized, phase III SIERRA trial that were presented at the 2019 Transplantation and Cellular Therapy Meetings.&nbsp;

Adding ibrutinib to&nbsp;CAR T-cell therapy led to improved responses in patients with relapsed/refractory chronic lymphocytic leukemia, according to preliminary findings presented at&nbsp;the 2019 Transplantation and Cellular Therapy Meetings.

In findings from a final PFS analysis of the phase III TOURMALINE-MM3 trial presented during the&nbsp;2019 Transplantation and Cellular Therapy Meetings, 2-year&nbsp;maintenance therapy with the oral proteasome inhibitor ixazomib following autologous stem cell transplantation improved progression-free survival in patients with multiple myeloma.

A supplemental new drug application for ivosidenib has been granted a priority review designation by the FDA&nbsp;for the frontline treatment of patients <em>IDH1</em>-mutant acute myeloid leukemia who are ineligible for standard chemotherapy, according to&nbsp;Agios, the manufacturer of ivosidenib.

Victor A. Chow, MD, discusses the next steps for chimeric antigen receptor T-cell therapy in patients with B-cell lymphomas.

The first attempt to quantify therapy-related myelodysplastic syndrome or acute myeloid leukemia in the era of widespread platinum-based chemotherapy has found that tMDS/AML risks were statistically significantly elevated after chemotherapy for 22 of 23 solid cancers, according to a new study in <em>JAMA Oncology.</em>

Maintenance therapy with lenalidomide (Revlimid) significantly improved progression-free survival compared with observation alone in patients with newly diagnosed multiple myeloma and the benefit was seen in both transplant-eligible and -ineligible groups.

Robert L. Ferris, MD, PhD, co-physician editor in chief of Targeted Therapies in Oncology, discusses exciting new findings and merit highlights reported in this month&#39;s issue.

A novel agent demonstrated efficacy in treating patients with early recurrent or refractory acute myeloid leukemia when administered via continuous intravenous infusion, according to results from a phase I/II trial recently published in <em>Cancer. </em>The agent was also well tolerated among patients.